---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007858"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:17:25.837556+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenon Pharmaceuticals adopts Executive Incentive Plan; sets 2023 salaries and 2022 bonuses for executives

## Summary
- CEO Ian Mortimer: 2022 non-equity bonus $343,422; 2023 base salary $665,000.
- CFO Sherry Aulin: 2022 bonus $178,619; 2023 base salary $465,000.
- CMO Christopher Kenney: 2022 bonus $195,300; 2023 base salary $510,000.
- CEO eligible for up to 60% base salary under new plan; CFO and CMO eligible for up to 40%.
- Incentive Compensation Plan allows cash awards based on corporate goals (R&D, regulatory, financial milestones).

## SEC filing metadata
- accession: 0000950170-23-007858
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017023007858/0000950170-23-007858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017023007858/xene-20230310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007858
- JSON: https://secwatch.observer/filing/0000950170-23-007858.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.